A Phase Ia/Ib, Open-label, Multicentre Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumours Expressing KRAS G12C Mutation
Latest Information Update: 19 Apr 2024
At a glance
- Drugs BI 1701963 (Primary) ; BI 1823911 (Primary) ; Midazolam
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 24 Oct 2023 Results (n=17; as of 23 Jan 2023) reporting preliminary data from part A (monotherapy portion) of this trial presented at the 48th European Society for Medical Oncology Congress
- 21 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 02 May 2023 Planned End Date changed from 26 Jul 2024 to 27 Dec 2024.